254 related articles for article (PubMed ID: 33313798)
21. Spotlight on Lonapegsomatropin Once-Weekly Injection and Its Potential in the Treatment of Growth Hormone Deficiency in Pediatric Patients.
Miller BS; Yuen KCJ
Drug Des Devel Ther; 2022; 16():2055-2066. PubMed ID: 35791404
[TBL] [Abstract][Full Text] [Related]
22. Once-Weekly Somapacitan as an Alternative Management of Growth Hormone Deficiency in Prepubertal Children: A Systematic Review and Meta-Analysis of Randomized Controlled Trial.
Tsurayya G; Nazhifah CA; Pirwanja MR; Zulfa PO; Tatroman MRR; Fakri F; Iqhrammullah M
Children (Basel); 2024 Feb; 11(2):. PubMed ID: 38397339
[TBL] [Abstract][Full Text] [Related]
23. Somapacitan in children born small for gestational age: a multi-centre, open-label, controlled phase 2 study.
Juul A; Backeljauw P; Højby M; Kawai M; Kildemoes RJ; Linglart A; Zuckerman-Levin N; Horikawa R
Eur J Endocrinol; 2023 Jan; 188(1):. PubMed ID: 36651161
[TBL] [Abstract][Full Text] [Related]
24. Monitoring serum insulin-like growth factor-I (IGF-I), IGF binding protein-3 (IGFBP-3), IGF-I/IGFBP-3 molar ratio and leptin during growth hormone treatment for disordered growth.
Tillmann V; Patel L; Gill MS; Whatmore AJ; Price DA; Kibirige MS; Wales JK; Clayton PE
Clin Endocrinol (Oxf); 2000 Sep; 53(3):329-36. PubMed ID: 10971450
[TBL] [Abstract][Full Text] [Related]
25. Pharmacokinetic and Pharmacodynamic Modeling of MOD-4023, a Long-Acting Human Growth Hormone, in Growth Hormone Deficiency Children.
Fisher DM; Rosenfeld RG; Jaron-Mendelson M; Amitzi L; Koren R; Hart G
Horm Res Paediatr; 2017; 87(5):324-332. PubMed ID: 28399519
[TBL] [Abstract][Full Text] [Related]
26. [Efficacy and safety of recombinant human growth hormone solution in children with growth hormone deficiency in China: a multicenter trial].
Hou L; Luo XP; Du ML; Ma HM; Gong CX; Li YC; Shen SX; Zhao ZH; Liang L; Dong GP; Yan CY; Du HW
Zhonghua Er Ke Za Zhi; 2009 Jan; 47(1):48-52. PubMed ID: 19573383
[TBL] [Abstract][Full Text] [Related]
27. Structure identification of circulating metabolites from somapacitan, a long-acting growth hormone derivative, and pharmacokinetics after single and multiple subcutaneous dosing in rats.
Helleberg H; Lindecrona RH; Thygesen P; Bjelke M
Eur J Pharm Sci; 2022 Jan; 168():106032. PubMed ID: 34610450
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of Safety and Efficacy of Growth Hormone Therapy by IGF-1 Z Score in Children with Short Stature.
Liu HJ; Wang LH; Chen L
Adv Ther; 2019 Sep; 36(9):2374-2383. PubMed ID: 31301056
[TBL] [Abstract][Full Text] [Related]
29. Plasma levels of insulin-like binding protein-2 in prepubertal short children and its diagnostic value in the evaluation of growth hormone deficiency.
van Doorn J; Ringeling AM; Rikken B; van Buul-Offers SC
Horm Res; 2001; 55(3):147-54. PubMed ID: 11549877
[TBL] [Abstract][Full Text] [Related]
30. A Randomized Safety and Efficacy Study of Somavaratan (VRS-317), a Long-Acting rhGH, in Pediatric Growth Hormone Deficiency.
Moore WV; Nguyen HJ; Kletter GB; Miller BS; Rogers D; Ng D; Moore JA; Humphriss E; Cleland JL; Bright GM
J Clin Endocrinol Metab; 2016 Mar; 101(3):1091-7. PubMed ID: 26672637
[TBL] [Abstract][Full Text] [Related]
31. Free dissociable insulin-like growth factor I (IGF-I), total IGF-I and their binding proteins in girls with Turner syndrome during long-term growth hormone treatment.
Bannink EM; van Doorn J; Stijnen T; Drop SL; de Muinck Keizer-Schrama SM
Clin Endocrinol (Oxf); 2006 Sep; 65(3):310-9. PubMed ID: 16918949
[TBL] [Abstract][Full Text] [Related]
32. Growth hormone therapy does not alter the insulin-like growth factor-I/insulin-like growth factor binding protein-3 molar ratio in growth hormone-deficient children.
Scirè G; Del Bianco C; Spadoni GL; Cianfarani S
J Endocrinol Invest; 2008 Feb; 31(2):153-8. PubMed ID: 18362507
[TBL] [Abstract][Full Text] [Related]
33. Safety and efficacy of growth hormone (GH) during extended treatment of adult Japanese patients with GH deficiency (GHD).
Chihara K; Kato Y; Kohno H; Takano K; Tanaka T; Teramoto A; Shimatsu A
Growth Horm IGF Res; 2008 Aug; 18(4):307-17. PubMed ID: 18282776
[TBL] [Abstract][Full Text] [Related]
34. IGF-I and IGF-binding protein-3 measurements on filter paper blood spots in children and adolescents on GH treatment: use in monitoring and as markers of growth performance.
Das U; Whatmore AJ; Khosravi J; Wales JK; Butler G; Kibirige MS; Diamandi A; Jones J; Patel L; Hall CM; Price DA; Clayton PE
Eur J Endocrinol; 2003 Sep; 149(3):179-85. PubMed ID: 12943519
[TBL] [Abstract][Full Text] [Related]
35. What do we do now that the long-acting growth hormone is here?
Miller BS
Front Endocrinol (Lausanne); 2022; 13():980979. PubMed ID: 36072938
[TBL] [Abstract][Full Text] [Related]
36. Elevated insulin-like growth factor-I values in children with Prader-Willi syndrome compared with growth hormone (GH) deficiency children over two years of GH treatment.
Feigerlová E; Diene G; Oliver I; Gennero I; Salles JP; Arnaud C; Tauber M
J Clin Endocrinol Metab; 2010 Oct; 95(10):4600-8. PubMed ID: 20926543
[TBL] [Abstract][Full Text] [Related]
37. Body composition and quality of life in adults with growth hormone deficiency; effects of low-dose growth hormone replacement.
Ahmad AM; Hopkins MT; Thomas J; Ibrahim H; Fraser WD; Vora JP
Clin Endocrinol (Oxf); 2001 Jun; 54(6):709-17. PubMed ID: 11422104
[TBL] [Abstract][Full Text] [Related]
38. GH response to provocation and circulating IGF-I and IGF-binding protein-3 concentrations, the IGF-I generation test and clinical response to GH therapy in children with beta-thalassaemia.
Soliman AT; El Banna N; Ansari BM
Eur J Endocrinol; 1998 Apr; 138(4):394-400. PubMed ID: 9578506
[TBL] [Abstract][Full Text] [Related]
39. Changes in serum insulin-like growth factor I (IGF-I) and IGF-binding protein-3 levels during growth hormone treatment in prepubertal short children born small for gestational age.
Boguszewski M; Jansson C; Rosberg S; Albertsson-Wikland K
J Clin Endocrinol Metab; 1996 Nov; 81(11):3902-8. PubMed ID: 8923836
[TBL] [Abstract][Full Text] [Related]
40. Circulating IGF-I, IGFBP-3 and the IGF-I/IGFBP-3 Molar Ratio Concentration and Height Outcome in Prepubertal Short Children on rhGH Treatment over Two Years of Therapy.
Ballerini MG; Braslavsky D; Scaglia PA; Keselman A; Rodríguez ME; Martínez A; Freire AV; Domené HM; Jasper HG; Bergadá I; Ropelato MG
Horm Res Paediatr; 2017; 88(5):354-363. PubMed ID: 28926833
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
